TP53 and hepatocellular carcinoma: When HCC cells were co-treated with ATAD2 siRNA and specific inhibitors of p53 (PFT-α and PFT-μ) or p38 (p168316), we observed that both p53 and p38 inhibitors could reverse the decrease in cell viability caused by ATAD2 suppression in HepG2 cells (Figure 4D).